BI-754111
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for BI-754111, covering 2025-12-19 to 2026-02-18. Get the full timeline:
Most recent: Clinical Trial Update: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) [Phase 1]